25. Đánh giá tính an toàn và một số tác dụng không mong muốn của phác đồ Mfolfoxiri + Bevacizumab điều trị ung thư đại tràng giai đoạn di căn tại Bệnh viện Đại học Y Hà Nội
Nội dung chính của bài viết
Tóm tắt
Colorectal cancer is one of the most common cancers in Vietnam. The cornerstone treatment for metastatic colon cancer patients is chemotherapy combined with targeted therapy. This study is a descriptive cross-sectional study with longitudinal follow-up conducted on 44 metastatic colon cancer patients receiving first-line treatment with the mFOLFOXIRI + Bevacizumab regimen at Hanoi Medical University Hospital from December 2023 to October 2024 to evaluate the safety of this regimen. The results showed that among 44 patients receiving a total of 254 chemotherapy cycles, the most common adverse event was anorexia, mostly at grades 1 and 2 (48.8%). The most frequent grade 3 and 4 toxicity was neutropenia (3.9%). Notably, no patient mortality due to adverse effects of the mFOLFOXIRI + Bevacizumab regimen in the treatment of metastatic colon cancer at Hanoi Medical University Hospital.
Chi tiết bài viết
Từ khóa
Ung thư đại tràng di căn, bevacizumab, mFOLFOXIRI, tác dụng không mong muốn
Tài liệu tham khảo
2. Marques RP, Duarte GS, Sterrantino C, et al. Triplet (FOLFOXIRI) versus doublet (FOLFOX or FOLFIRI) backbone chemotherapy as first-line treatment of metastatic colorectal cancer: A systematic review and meta-analysis. Critical Reviews in Oncology/Hematology. 2017; 118: 54-62. doi:10.1016/j.critrevonc.2017.08.006.
3. Baraniskin A, Buchberger B, Pox C, et al. Efficacy of bevacizumab in first-line treatment of metastatic colorectal cancer: A systematic review and meta-analysis. European Journal of Cancer. 2019; 106: 37-44. doi:10.1016/j.ejca.2018.10.009.
4. Ogata T, Satake H, Ogata M, et al. Safety and effectiveness of FOLFOXIRI plus molecular target drug therapy for metastatic colorectal cancer: A multicenter retrospective study. Oncotarget. 2019; 10(10): 1070-1084. doi:10.18632/oncotarget.26626.
5. Cremolini C, Loupakis F, Antoniotti C, et al. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. Lancet Oncol. 2015; 16(13): 1306-1315. doi:10.1016/S1470-2045(15)00122-9.
6. Shinozaki K, Yamada T, Nasu J, et al. A phase II study of FOLFOXIRI plus bevacizumab as initial chemotherapy for patients with untreated metastatic colorectal cancer: TRICC1414 (BeTRI). Int J Clin Oncol. 2021; 26(2): 399-408. doi:10.1007/s10147-020-01811-w.
7. Kobayashi K, Yamaguchi S, Ito S, et al. Efficacy and Safety of Modified FOLFOXIRI+α in the Treatment of Advanced and Recurrent Colorectal Cancer: A Single-center Experience. Intern Med. 2020; 59(10): 1239-1245. doi:10.2169/internalmedicine.3274-19.
8. Huy TL, Bui MH, Chu Dinh T, Xuyen HTH. Efficacy and Toxicity of Folfoxiri for Patients with Metastatic Colorectal Cancer. Open Access Maced J Med Sci. 2019; 7(24): 4244-4249. doi:10.3889/oamjms.2019.368.
9. Nahler G, ed. WHO-toxicity scale. In: (2009). WHO-Toxicity Scale. In: Dictionary of Pharmaceutical Medicine. Springer, Vienna. Https://Doi.Org/10.1007/978-3-211-89836-9_1474. Vienna: Springer; 2009: 194-194. doi:10.1007/978-3-211-89836-9_1474.
10. Common Terminology Criteria for Adverse Events (CTCAE). 2017.
11. Sunakawa Y, Satake H, Usher J, et al. Dynamic changes in RAS gene status in circulating tumour DNA: a phase II trial of first-line FOLFOXIRI plus bevacizumab for RAS-mutant metastatic colorectal cancer (JACCRO CC-11). ESMO Open. 2022; 7(3): 100512. doi:10.1016/j.esmoop.2022.100512.